Articles from Mursla Bio

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve chronic disease outcomes for at-risk patients, today announced it has been selected to join the Association of British HealthTech Industries (ABHI) US Accelerator. Building on the Company’s US presence, the programme will support the introduction of EvoLiver™, its FDA-designated liver cancer surveillance test, to the US market.

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve cancer outcomes for at-risk patients, today announced the commercial launch of its AI Precision Medicine Platform, alongside a pre-print¹ reporting the first validated method for isolating hepatocyte EVs from plasma for organ-specific proteomic and miRNA profiling. Mursla Bio is engaging with potential partners to apply its Platform to additional disease areas, biomarker discovery and IVD translation programs.

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of Dynamic Biopsy technology, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its lead product, EvoLiver™. The designation recognizes the potential of the Company’s Dynamic Biopsy-based blood test, EvoLiver, which is enabled by a novel platform based on organ-specific EVs for the surveillance of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, in high-risk cirrhotic patients.

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, today announced results of its multi-centre clinical study, MEV01, in collaboration with leading academic institutes including University College London, Imperial College London, University Hospital of Santa Maria and the Medical University of Graz. The ongoing study is investigating the Company’s dynamic biopsy-based blood test, EvoLiver™, for the surveillance of primary liver cancer, Hepatocellular Carcinoma (HCC), among high-risk, cirrhotic patients. Mursla Bio established the first EV multiomics biomarker signature for HCC with 86% early-stage sensitivity and 88% specificity, significantly surpassing existing surveillance techniques including ultrasound and alpha-fetoprotein testing.

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, announced it has been invited to join EVEREST, a leading European consortium. The consortium’s objective is to advance EV research, innovation and clinical translation for the benefit of patients. Mursla Bio’s selection demonstrates the Company’s leadership in the field, particularly in developing EV-based disease surveillance and diagnostic tests.